Two neuromuscular diseases with overlapping immune-mediated mechanisms can have strikingly opposite effects on lifespan — and a large death-certificate analysis now quantifies that divergence with unusual precision. For neurologists, patients, and longevity researchers, this challenges the assumption that chronic autoimmune neurological conditions uniformly shorten life.
Analyzing death certificates across four U.S. states — Florida, Wisconsin, Texas, and New York — for the years 2000, 2005, 2010, and 2015, investigators identified individuals whose records listed myasthenia gravis (MG) or multiple sclerosis (MS) as a contributing or primary cause of death. After adjusting for sex and geography and benchmarking against Social Security actuarial life tables, the contrast was stark. MS patients died an average of 12.4 years earlier than the general population (p < 0.001), a finding consistent with prior epidemiological literature. MG patients, however, died approximately 4.8 years later than population norms (p < 0.0001) — and fully 15.5 years later than MS patients. Crucially, this data predates the era of high-efficacy biologics for both conditions, meaning the mortality signals reflect standard immunosuppressive and symptomatic care rather than modern targeted therapies.
The longevity advantage in MG is genuinely counterintuitive and warrants careful interpretation. One plausible explanation is survivorship bias: MG is frequently diagnosed in older adults — particularly in men over 60 — meaning the disease-associated death cohort is already enriched with individuals who lived long enough to acquire the condition. Additionally, MG's primary lethality risk, myasthenic crisis, is an acute respiratory event that is increasingly well-managed in modern ICUs, potentially removing it as a major mortality driver before the study window. The MS comparison, by contrast, reflects a disease with younger onset and progressive neurological deterioration that accumulates over decades. This study is retrospective and observational, so causality cannot be inferred, and listing on a death certificate does not guarantee MG or MS was the proximate cause of death. Nonetheless, the population-level effect sizes are large enough to be clinically meaningful and suggest MG's net longevity impact may be far more benign than its acute severity implies.
